Common ABCB1 polymorphisms associated with susceptibility to infantile spasms in the Chinese Han population

L Dong1, M Mao, R Luo

  • 1Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.

Insights

Genetic variations in the ABCB1 gene, specifically the C3435T polymorphism, are linked to infantile spasms in Chinese children. The 3435TT genotype increases the risk for this severe epilepsy syndrome.

Area of Science:

  • Genetics
  • Neurology
  • Pharmacogenomics

Background:

  • Infantile spasms (IS) are a severe epileptic encephalopathy in infants and young children.
  • IS often leads to intractable epilepsy and is frequently refractory to standard antiepileptic drugs.
  • The P-glycoprotein gene (ABCB1) is implicated in drug resistance, but its role in IS pathogenesis is unclear.

Purpose of the Study:

  • To investigate the association between common ABCB1 gene polymorphisms and the risk of infantile spasms.
  • To explore the influence of host factors, like epilepsy syndrome, on this association.
  • To analyze ABCB1 polymorphisms (C1236T, G2677T/A, C3435T) in a Han Chinese pediatric population.

Main Methods:

  • Case-control study design.
  • Inclusion of 91 infantile spasm patients and 368 healthy controls from a Han Chinese population.
  • DNA analysis using PCR-RFLP to genotype three specific ABCB1 polymorphisms.

Main Results:

  • Significant differences in genotype distribution for the C3435T polymorphism were found between cases and controls.
  • The 3435TT genotype was associated with an increased risk of infantile spasms (OR=2.47, P=0.001).
  • The 3435CT genotype showed a decreased risk (OR=0.28, P<0.001).
  • No significant differences were observed in allelic or haplotypic frequencies.

Conclusions:

  • Variations in the ABCB1 C3435T gene are significantly associated with infantile spasms in the Han Chinese population.
  • The 3435TT genotype is a risk factor for developing infantile spasms.
  • These findings highlight the role of ABCB1 genetic variations in the pathogenesis of infantile spasms.

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...